中国中药杂志

2021, v.46(03) 685-693

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

中医药辅助治疗难治性高血压病临床疗效的Meta分析
Meta-analysis for clinical efficacy of traditional Chinese medicine in treating resistant hypertension

王梦玺;吴晨洁;曹培华;陈晓虎;
WANG Meng-xi;WU Chen-jie;CAO Pei-hua;CHEN Xiao-hu;Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Province Hospital of Chinese Medicine);

摘要(Abstract):

为系统评价中医药疗法对难治性高血压病患者的疗效及安全性,使用计算机检索中国知网、万方、维普、CBM、PubMed、Web of Science、Cochrane Library、EMbase等数据库,筛选出应用中医药疗法辅助治疗难治性高血压病的随机对照试验,采用Cochrane Handbook评价标准对纳入文献进行质量评价,运用RevMan 5.3和Stata 12.0软件进行Meta分析。最终纳入符合标准的文献11篇,包含1 023例患者,Meta分析结果显示,在标准三联降压方案基础上,联合使用中医药疗法能进一步降低难治性高血压病患者的收缩压(MD=-16.69,95%CI[-22.21,-11.16],P<0.000 01]、降低舒张压(MD=-7.51,95%CI[-8.26,-6.76],P<0.000 01)、提高降压有效率(OR=5.16,95%CI[3.01,8.84],P<0.000 01)、提高血压达标率(OR=3.01,95%CI[1.49,6.09],P=0.002)、提高临床症状有效率(OR=4.48,95%CI[2.31,8.68],P<0.000 01),但对血肌酐水平无显著影响(MD=-2.51,95%CI[-6.91,1.89],P=0.26)。结果表明,在标准三联降压方案基础上联用中医药疗法可以进一步改善难治性高血压病患者的临床疗效且具有良好的安全性,但仍需更多高质量的临床研究加以验证。
To systematically evaluate the efficacy and safety of traditional Chinese medicine in treating patients with resistant hypertension. CNKI, Wanfang, VIP, CBM, PubMed, Web of Science, Cochrane Library, EMbase and other databases were retrieved by computers to screen out the randomized controlled trial of traditional Chinese medicine in treating resistant hypertension. Cochrane Handbook was used to evaluate the quality of the included literature, RevMan 5.3 and Stata 12.0 was used for Meta-analysis. Finally, 11 literatures meeting the criteria were included, involving 1 023 patients. The results of Meta-analysis showed that the combined therapy of standard triple antihypertensive regimen with traditional Chinese medicine could further reduce systolic blood pressure of patients with resistant hypertension(MD=-16.69, 95%CI[-22.21,-11.16], P<0.000 01), reduce diastolic blood pressure(MD=-7.51, 95%CI[-8.26,-6.76], P<0.000 01), improve the effective rate of anti-hypertension(OR=5.16, 95%CI[3.01, 8.84], P<0.000 01), improve the up-to-standard rate of blood pressure(OR=3.01, 95%CI[1.49, 6.09], P=0.002), and improve the effectiveness of clinical symptoms(OR=4.48, 95%CI[2.31, 8.68], P<0.000 01), with no significant effect on creatinine level(MD=-2.51, 95%CI[-6.91, 1.89], P=0.26). The results of this study indicated that the combined therapy of standard triple antihypertensive regimen with traditional Chinese medicine could further improve the clinical efficacy in patients with resistant hypertension with a good safety, but more high-quality clinical studies are still needed to verify this conclusion.

关键词(KeyWords): 中医药;难治性高血压病;Meta分析
traditional Chinese medicine;resistant hypertension;Meta-analysis

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目(81973824);; 国家中医药管理局中医药循证能力建设项目(2019XZZX-XXG004)

作者(Author): 王梦玺;吴晨洁;曹培华;陈晓虎;
WANG Meng-xi;WU Chen-jie;CAO Pei-hua;CHEN Xiao-hu;Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Province Hospital of Chinese Medicine);

Email:

DOI: 10.19540/j.cnki.cjcmm.20200521.501

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享